Table 3.

Effects of Baseline and Discharge Anemia on Outcomes for Patients With HF With Systolic Dysfunction

Outcomes	Independent Bivariable*		Adjusted for EVEREST Covariates† Plus Discharge Anemia Status
	HR (95% CI)	P Value	HR (95% CI)	P Value
All-cause mortality
Baseline anemia	1.13 (0.93–1.38)	0.21	0.94 (0.76–1.15)	0.53
Discharge anemia	1.65 (1.35–2.02)	<0.001	1.30 (1.05–1.60)	0.015
CV mortality or HF hospitalization
Baseline anemia
≤100 d	1.09 (0.87–1.36)	0.45	0.92 (0.73–1.16)	0.47
>100 d	1.13 (0.91–1.41)	0.28	0.95 (0.76–1.19)	0.65
Discharge anemia
≤100 d	2.15 (1.72–2.69)	<0.001	1.73 (1.37–2.18)	<0.001
>100 d	1.42 (1.13–1.78)	0.003	1.22 (0.96–1.54)	0.11

CI indicates confidence interval; CV, cardiovascular; EVEREST, Efficacy of Vasopressin Antagonist in Heart Failure Outcome Study with Tolvaptan; HF, heart failure; and HR, hazard ratio.

^*Both baseline and discharge anemia status were simultaneously analyzed in this model to assess their predictive value independent of the other measurement. Patient who died in-hospital were excluded from this analysis.

^†Adjusted for variables noted in the Methods section.